All In Biotech

Drug Trial Radar · NCT04020055

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-Stage Renal Disease Treated With Hemodialysis

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

Oct 31, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)

Conditions

  • Fabry Disease

Interventions

  • migalastat HCl 150 mgDrug

    migalastat HCl 150 mg capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax)Time frame: Baseline through Month 12
  2. Time to maximum concentration (tmax)Time frame: Baseline through Month 12
  3. Apparent terminal elimination half-life (t½)Time frame: Baseline through Month 12
  4. Concentration at the end of a dosing interval at steady state (Ctrough)Time frame: Baseline through Month 12
  5. Average plasma migalastat concentration over the dosing interval (Cavg)Time frame: Baseline through Month 12
  6. Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ)Time frame: Baseline through Month 12
  7. Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞)Time frame: Baseline through Month 12
  8. Apparent plasma clearance (CL/F)Time frame: Baseline through Month 12
  9. Apparent terminal phase volume of distribution (Vz/F)Time frame: Baseline through Month 12
  10. Dialysis clearance (CLD)Time frame: Baseline through Month 12
  11. Volume of dialysate collected during the interval (VD)Time frame: Baseline through Month 12
  12. Mean migalastat concentration in dialysate (CD)Time frame: Baseline through Month 12
  13. Amount recovered in dialysate (AeD)Time frame: Baseline through Month 12
  14. Fraction of the dose recovered in dialysate (FeD)Time frame: Baseline through Month 12
  15. Mean migalastat plasma concentration during the dialysis interval (P)Time frame: Baseline through Month 12
  16. Mean inlet area under the curve (AUCinlet)Time frame: Baseline through Month 12
  17. Mean outlet area under the curve (AUCoutlet)Time frame: Baseline through Month 12
  18. Extraction ratio (ED)Time frame: Baseline through Month 12
  19. Dialyzer blood flow (QD)Time frame: Baseline through Month 12
  20. Cumulative amount excreted over all collection intervals (Ae0-τ)Time frame: Baseline through Month 12
  21. Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ)Time frame: Baseline through Month 12
  22. Renal clearance (CLr)Time frame: Baseline through Month 12

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia

  • The Cleveland Clinic

    Cleveland, Ohio

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc

    Fairfax, Virginia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Royal Perth Hospital

    Perth, Washington, Australia

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Shizuoka General Hospital

    Shizuoka, Shizuoka, Japan

  • Centro Hospitalar e Universitário de Coimbra (CHUC)

    Coimbra, Portugal

  • Hospital Universitari(o) de Bellvitge (HUB) Feixa Llarga

    Barcelona, Spain

  • Hospital General Universitario de Elda

    Elda, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Salford Royal Hospital

    Salford, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.